6P8N image
Deposition Date 2019-06-07
Release Date 2019-11-20
Last Version Date 2024-10-23
Entry Detail
PDB ID:
6P8N
Keywords:
Title:
Crystal Structure of Antibody P-p1f1 in Complex with eOD-GT8
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.20 Å
R-Value Free:
0.28
R-Value Work:
0.22
R-Value Observed:
0.22
Space Group:
P 2 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Env outer domain eOD-GT8
Chain IDs:A (auth: C), D (auth: A)
Chain Length:183
Number of Molecules:2
Biological Source:Human immunodeficiency virus 1
Polymer Type:polypeptide(L)
Molecule:P-p1f1 Heavy Chain
Chain IDs:B (auth: H), E (auth: B)
Chain Length:226
Number of Molecules:2
Biological Source:Mus musculus
Polymer Type:polypeptide(L)
Molecule:P-p1f1 Light Chain
Chain IDs:C (auth: L), F (auth: D)
Chain Length:216
Number of Molecules:2
Biological Source:Mus musculus
Primary Citation
Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization.
Cell Rep 29 3060 3072.e7 (2019)
PMID: 31801073 DOI: 10.1016/j.celrep.2019.10.071

Abstact

Broadly HIV-1 neutralizing VRC01 class antibodies target the CD4-binding site of Env. They are derived from VH1-2∗02 antibody heavy chains paired with rare light chains expressing 5-amino acid-long CDRL3s. They have been isolated from infected subjects but have not yet been elicited by immunization. Env-derived immunogens capable of binding the germline forms of VRC01 B cell receptors on naive B cells have been designed and evaluated in knockin mice. However, the elicited antibodies cannot bypass glycans present on the conserved position N276 of Env, which restricts access to the CD4-binding site. Efforts to guide the appropriate maturation of these antibodies by sequential immunization have not yet been successful. Here, we report on a two-step immunization scheme that leads to the maturation of VRC01-like antibodies capable of accommodating the N276 glycan and displaying autologous tier 2 neutralizing activities. Our results are relevant to clinical trials aiming to elicit VRC01 antibodies.

Legend

Protein

Chemical

Disease

Primary Citation of related structures